Inhibitors of GPIIb/IIIa platelet receptors;Inhibiteurs des recepteurs gp IIb/IIIa plaquettaires

Archives des Maladies du Coeur et des Vaisseaux

Volumn 92, Issue 7, 1999, Pages 893-902

  Chanu, B ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBOCYTE RECEPTOR; TIROFIBAN; ACETIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; LAMIFIBAN; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; FIBRIN METABOLISM; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; REVIEW; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; ARTICLE; CEREBROVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; HEART INFARCTION; THROMBOCYTE ADHESIVENESS; THROMBOCYTOPENIA;

ACETATES; ANTIBODIES, MONOCLONAL; CEREBROVASCULAR DISORDERS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TYROSINE;

EID: 0033161476     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Schafer AL. Antiplatelet therapy. Am J Med 1996; 101: 1161-201.
2. e ed). New York : McGraw Hill, 1996: 1161-201.
3. Tcheng JE. Platelet Integrin glycoprotein IIb/IIIa inhibitors : opportunities and challenges. J Inv Cardiol 1996; vol 8 (suppl B): 8B-14B.
4. Coller BS, Anderson KM, Weisman HF. The anti-GpIIb/IIIa agents : fundamental and clinical aspects. Haemostasis 1996; 25 (supp 4): 285-93.
5. Steinhubl SR, Moliterno DJ. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina. Heart Vessels 1997; suppl 12: 148-55.
6. Coller B.S. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Art Dis 1992; 3: 1016-29.
7. Tcheng JE, Kereiakes DJ, George BS et al. Safety of readministration of abciximab-interim results of the Reopro Readministration Registry (R3). Presented at the American College of Cardiology-Atlanta 1998. (in press).
8. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
9. Lincoff AM, Califf RM, Anderson KM et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7e3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30: 149-56.
10. Topol EJ, Califf RM, Weisman HF et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
11. Topol EJ, Ferguson JJ, Weisman HF et al. Long term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-84.
12. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
13. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention refractory instable angina: the CAPTURE Study. Lancet 1997; 349, 9063: 1429-35.
14. Hamm CW, Hoëschen C, Goldmann D et al. Troponin T predicts benefit of abciximab in patients with unstable angina in the CAPTURE study (abstract 766). Eur Heart J 1998; 19 (suppl.): 117.
15. Stubbs P, Collinson P, Mosely D et al. Prospective study of the role of cardiac troponin T in patients admitted with instable angina. BMJ 1996; 313: 262-4.
16. The EPISTENT Investigators. Randomised placebo-controlled and ballon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87-92.
17. EPISTENT Investigators. Presented at the European Symposium of Cardiology. Vienna, août 1998 (in press).
18. The Impact-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. LANCET 1997; 349: 1422-8.
19. ADGEY AAJ. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Eur Heart J 1998; 19 (suppl D): DTO-D21.
20. Califf RM. PURSUIT. Presented at the 70th Scientific Sessions of the American Heart Association ; November 9-12, 1997 ; Orlando, Florid.
21. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
22. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53.
23. Gibson CM, Goel M, Cohen DJ et al for the RESTORE Investigators. Six month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the Restore trial. J Am Coll Cardiol 1998; 32: 28-34.
24. The platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J med 1998; 338: 1498-505.
25. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
26. Cody RJ. Results from late breaking clinical trials sessions at ACC 97. J Am Coll Cardiol 1997; 30 (1): 1-7.
27. Jackson G. Tirofiban : Spinning the data from fact to hype. B J Clin Prat 1997; 51, 3: 131-2.
28. Van de Werf F. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes. Thromb Hæmost 1997; 78: 210-3.
29. Van de Werf F. PARAGON. Presented at the 19th Congress of the European Society of Cardiology ; August 24-28 1997; Stockholm, Suède.
30. Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am J Cardiol 1996; 78 (S3A): 35-40 .
31. Pinton P. Thrombopénie sous abciximab dans le traitement des syndromes coronariens aigus par angioplastie. Ann Cardiol Angeiol 1998; 47: 351-8.
32. Giugliano RP, Hyatt RR Jr. Thrombocytopenia with GpIIb/IIIa inhibitors: a Meta-Analysis. Presented at the American College of Cardiology, Atlanta 1998 (in press).